FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 570 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading ESMO Welcomes European Parliament Resolution Marking World Cancer Day MOST POPULAR Some Brain Cells May Help to Fuel Cancer Metastasis November 21, 2019 This Saturday: National Prescription Drug Take-Back Day October 22, 2020 FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma February 2, 2024 2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical... May 26, 2022 Load more HOT NEWS 30-Year-Old Mom of 7 With Terminal Breast Cancer Is Gifted Dream... EMA Recommends Granting a Conditional Marketing Authorisation for Futibatinib How Living in Service to Others Helped Me Cope During Cancer Cancer in My Community: Caring for the Whole Patient in Brazil
